TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Ra Medical Systems, Inc. (NYSE: RMED) Investor Securities Class Action Lawsuit 06/10/2019

  • If you purchased shares of Ra Medical Systems, Inc. (NYSE: RMED), you may have certain options. Please contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Company
Ra Medical Systems, Inc.
Security
NYSE: RMED

Case Name
Ra Medical Systems Shareholder Class Action Lawsuit 06/10/2019
Type of Lawsuit
Shareholder Class Action
Court of Filing
U.S. District Court for the Southern District of California

Class Period Begin
Class Period End
Deadline To File for Lead
You must register or login to receive notifications.

Click here to subscribe to Ra Medical Systems, Inc..
Summary

April 19, 2021 - A second amended complaint was filed.

March 24, 2021 - The court granted in part and denied in part the defendants' motion to dismiss.

March 13, 2020 - A motion to dismiss the amended complaint was filed.

January 13, 2020 - An amended complaint was filed.

June 7, 2019 - An investor in shares of Ra Medical Systems, Inc. (NYSE: RMED) filed a lawsuit in the U.S. District Court for the Southern District of California over alleged violations of Federal Securities Laws by Ra Medical Systems, Inc. in connection with certain allegedly false and misleading statements made in connection with the Company’s September 2018 initial public offering (“IPO” or the “Offering”). In September 2018, Ra Medical completed its initial public offering (“IPO”), issuing approximately 4.5 million shares of common stock priced at $17 per share.

On March 14, 2019, the Company revealed that its fourth quarter 2018 financial results had been negatively impacted by issues related to the hiring and training of qualified sales personnel and certain production limitations.

According to the complaint the plaintiff alleges on behalf of purchasers of Ra Medical Systems, Inc. (NYSE: RMED) common shares, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that the Defendants failed to disclose to investors that the Company’s evaluation of sales personnel candidates was inadequate, that the Company’s training program for sales personnel was inadequate, that, as a result, the Company could not reasonably assure that its newly hired sales personnel were adequately experienced, that, as a result, the Company would suffer a shortage of qualified sales personnel, that the Company’s manufacturing process could not reasonably support increased catheter production, that, as a result, the Company would suffer production delays, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.